Navigation Links
Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
Date:10/2/2008

asts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the expected benefits of Dyax's collaboration with Athera and the prospects for development of antibodies to phosphorylcholine include the risks that: products from this collaboration may not show therapeutic effect or an acceptable safety profile in clinical trials or could take a significantly longer time to gain regulatory approval than Dyax expects or may never gain approval; products developed in this collaboration may not gain market acceptance; others may develop products superior to those being developed in this collaboration; Dyax is dependent on the expertise, effort, priorities and contractual obligations of Athera in the development of products arising out of this collaboration; Dyax and Athera may not be able to obtain and maintain intellectual property protection for the products of this collaboration; and other risk factors described or referred to in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law. Dyax specifically disclaims responsibility for information describing Athera and its business other than the license with Dyax.

Dyax and the Dyax logo are the registered trademarks of Dyax Corp.

About Athera Biotechnologies

Athera Biotechnologies AB develops novel products for risk assessment
'/>"/>

SOURCE Athera Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Charlene Vernak, RPh, of Vernak Farms ... recently was awarded the George Roentsch Scholarship by the ... award in Houston during PCCA,s ... awarded annually to an independent pharmacist and PCCA member ... George Roentsch , a well-known pharmacist in the compounding ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
(Date:10/22/2014)... October 22, 2014 Oramed ... a clinical-stage pharmaceutical company focused on the development ... top-line clinical results from its Phase IIa clinical ... capsules, to treat type 1 diabetes. The trial was ... under a U.S. Food and Drug Administration ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
... Novavax, Inc. (Nasdaq: NVAX) ... and immunogenicity results from its 2009 H1N1 virus-like particle ... the invitation-only 7th World Health Organization Meeting (WHO) on ... meeting was held at the WHO headquarters in Geneva, ...
... BEIJING, Feb. 18, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, announced its ... December 31, 2010 ("3Q FY2010") today. ... Months EndedDecember 31, 2009December 31, ...
Cached Medicine Technology:NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 2NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 3NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 4NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 5China Medical Technologies Reports Third Fiscal Quarter Financial Results 2China Medical Technologies Reports Third Fiscal Quarter Financial Results 3China Medical Technologies Reports Third Fiscal Quarter Financial Results 4China Medical Technologies Reports Third Fiscal Quarter Financial Results 5China Medical Technologies Reports Third Fiscal Quarter Financial Results 6China Medical Technologies Reports Third Fiscal Quarter Financial Results 7China Medical Technologies Reports Third Fiscal Quarter Financial Results 8China Medical Technologies Reports Third Fiscal Quarter Financial Results 9China Medical Technologies Reports Third Fiscal Quarter Financial Results 10China Medical Technologies Reports Third Fiscal Quarter Financial Results 11China Medical Technologies Reports Third Fiscal Quarter Financial Results 12China Medical Technologies Reports Third Fiscal Quarter Financial Results 13China Medical Technologies Reports Third Fiscal Quarter Financial Results 14China Medical Technologies Reports Third Fiscal Quarter Financial Results 15China Medical Technologies Reports Third Fiscal Quarter Financial Results 16China Medical Technologies Reports Third Fiscal Quarter Financial Results 17China Medical Technologies Reports Third Fiscal Quarter Financial Results 18China Medical Technologies Reports Third Fiscal Quarter Financial Results 19China Medical Technologies Reports Third Fiscal Quarter Financial Results 20China Medical Technologies Reports Third Fiscal Quarter Financial Results 21China Medical Technologies Reports Third Fiscal Quarter Financial Results 22
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- The United States ... from Ebola-affected nations of West Africa land at ... for infection with the virus. In a ... noted that 94 percent of air passengers from ... one of these five airports -- New York ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 During the ... fresh water supply runs dangerously low, Southern Oregon’s water ... Oregon’s rivers, despite the lowest mountain snow pack on ... late summer and early autumn.* That was the observation ... the new book “Hiking Southern Oregon,” during an interview ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
(Date:10/22/2014)... (HealthDay News) -- Two sisters in high school have ... Ilina and Medha Krishen use electronic stethoscopes, which electronically ... in breathing patterns or heartbeats. Ilina, a senior ... to find a way to detect early lung damage ... electronic stethoscope, Ilina recorded one breath cycle each from ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... community for people who support affordable health insurance options for American ... ... 10, 2008 -- While politicians dispense their health care ideas at ... the same online. The common place to do so is at ...
... Forest, NC company specializing in risk assessment for diabetics, recently announced ... Retasure™ solution to provide retinal imaging risk assessment. , ... ... -- Digital Healthcare, a Wake Forest, NC company specializing in ...
... of free clinics is now available on ... that assist with the costs of medicine. The ... and is the most extensive list available in ... addition to NeedyMeds’ already extensive listings of patient ...
... ,Essilor is pursuing its growth strategy in Eastern ... Optix. The company is a leading,operator in the ... total revenue of more than EUR10 million., ... a recognized market,player, the acquisition will enable Essilor ...
... of checkpoint signaling and DNA repair mechanisms to ... branches in the checkpoint response pathwayataxia telangiectasia-mutated (ATM) ... to interact with DNA damage sensing and repair ... circumvent, or exploit various aspects of the DNA ...
... Sept. 9 Brazos Valley residents,neuroscience researchers, and ... internationally recognized researchers on the,topic of stroke during ... Symposium on Sept. 19. This year,s symposium will ... an afternoon session for clinicians,and researchers. The speakers ...
Cached Medicine News:Health News:Social Network For Affordable Health Care Supporters Stimulates A New Level of Interactivity and Dialogue 2Health News:The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients 2Health News:Urgently Needed Database Now Available for People Who Cannot Afford Health Care at NeedyMeds.com 2Health News:A potential approach to treatment of hepatitis B virus infection 2Health News:Texas Brain and Spine Institute to Hold Second Annual Neuroscience Symposium 2
... Eliminate the need for makeshift, modified nebulizer ... waste time gathering parts when your patient ... to deliver the utmost in Heliox rescue ... is fast becoming the standard of care ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... with metered dose inhalers., ,ACE ensures ... MDI canisters. Its versatile design allows it ... in conjunction with an endotracheal airway or ... ACE may also be used in conjunction ...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only...
Medicine Products: